Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Therapeutic Value of Sirolimus in Refractory Adult-Onset Still's Disease

NCT07151157 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT07151157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07151157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Therapeutic Value of Sirolimus in Refractory Adult-Onset Still's Disease
Lead sponsor
Ruijin Hospital
Phase
Not applicable
Overall status
Active, not recruiting
Start date
August 30, 2025
Completion date
August 30, 2026
Enrollment
3 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult-onset still's disease